<?xml version="1.0" encoding="UTF-8"?>
<p id="heading-b95cc94bea367dba3fde354e9d61ff6c">Abidol is a broad-spectrum antiviral drug. By inhibiting the fusion between the influenza virus and host cells, it can inhibit virus replication. It has been used to prevent/treat both SARS and Middle East Respiratory Syndrome (MERS). According to an online report, Abidol in the concentration range of 10-30Î¼M not only inhibited COVID-19 duplication, it also significantly reduced the pathological effect of the virus
 <sup>
  <xref rid="R5497" id="xref-c808352c21ae971bbc27a8ba3d06ddac" ref-type="bibr">9</xref>
 </sup>. A randomized multi-center controlled clinical trial wtih Abidol in patients with COVID-19 has started in Xiangya Hospital in China, which has been registered in the US clinical trial database
 <sup>
  <xref rid="R5498" id="xref-93f26bd4670cff25c3efa39c648f8fd4" ref-type="bibr">10</xref>
 </sup>.
</p>
